Trial site
L2IP - Instituto de Pesquisas Clínicas
- 15running trials
- 3closed trials
The trials here
What the 18 trials at this site are about, from their registry records.
- Conditions
- Ulcerative colitis6 trials
- Crohn's disease5 trials
- Obesity4 trials
- Alzheimer disease2 trials
- Heart failure2 trials
- Type 2 diabetes2 trials
- Chronic kidney disease1 trial
- Coronary artery disease1 trial
- Depression1 trial
- Insomnia1 trial
- Peripheral artery disease1 trial
- Stroke1 trial
- Phase
- Phase 312 trials
- Phase 23 trials
- Phase 2/33 trials
- Status
- Active, not recruiting7 trials
- Recruiting7 trials
- Completed3 trials
- Not yet recruiting1 trial
- Lead sponsor
- Janssen Research & Development, LLC9 trials
- Eli Lilly and Company6 trials
- Bristol-Myers Squibb2 trials
- Pfizer1 trial
Running trials
Recruiting
A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease
Recruiting
A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease
Active, not recruiting
Recruiting
Recruiting
Recruiting
Recruiting
Recruiting
Recruiting
A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)
Active, not recruiting
Active, not recruiting
Active, not recruiting
A Study of Guselkumab Therapy in Participants With Moderately to Severely Active Ulcerative Colitis
Active, not recruiting
A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease
Active, not recruiting
A Study of Guselkumab in Participants With Moderately to Severely Active Ulcerative Colitis
Active, not recruiting
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
- Crohn's disease3 recruiting
- Obesity3 recruiting
- Alzheimer disease2 recruiting
- Heart failure1 recruiting
- Ulcerative colitis1 recruiting
Closed trials
Recruiting
Completed
Completed
A Study of JNJ-77242113 in Participants With Moderately to Severely Active Ulcerative Colitis
Site data: ClinicalTrials.govUpdated 18 Nov 2026